aTyr Pharma, Inc. (LIFE) News
Filter LIFE News Items
LIFE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LIFE News From Around the Web
Below are the latest news stories about ATYR PHARMA INC that investors may wish to consider to help them evaluate LIFE as an investment opportunity.
aTyr Pharma's Market Cap Drops To US$66m Leaving Insiders With LossesInsiders who bought US$501.6k worth of aTyr Pharma, Inc.'s ( NASDAQ:LIFE ) stock at an average buy price of US$2.23... |
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology (ACR) Convergence 2 |
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdatePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient dosing. Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments. SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of firs |
aTyr Pharma to Present at November Investor ConferencesSAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences scheduled to take place in November 2023. Details of the presentations appear below: Conference: Jefferies London Healthcare C |
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDMultiple centers in the U.S. are open for enrollmentSAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT™ study. The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company’s lead the |
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY. Details of the presentation appear below: C |
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue EstimatesAtyr Pharma (LIFE) delivered earnings and revenue surprises of 18.52% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate UpdatePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and investments. SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in- |